In this interview, Allen J. Taylor, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Clinical Cardiology Takeaways from 2025 including trials SCOT-HEART 2, ALONE-AF, Launch-HTN, and more.

In this interview, Deepak Bhatt, MD, MPH, FACC and Alison L. Bailey, MD FACC, discuss the Top Interventional Cardiology Takeaways from 2025 including DanGer Shock trial, revascularization in STEMI, ...

The following are key points from the 2025 ACC/AHA/ASE/ASNC/SCCT/SCMR Advanced Training Statement on Advanced Cardiovascular Imaging: A Report of the ACC Competency ...

Innovation in Action is a podcast series hosted by the ACC Innovation Program aimed at exploring innovations shaping care delivery. In this episode, Drs. Rupal O'Quinn and Leon Ptaszek join ACC Chief ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...

During ACC's 75th Anniversary, we're celebrating our legacy and preparing to shape the next 75 years. Help us invest in the future of cardiology with a gift to the ACC Foundation. Gifts support a ...

Between 2% to 3% of all patients and 5% to 6% of all women who present with what looks like an acute coronary syndrome (ACS) are actually suffering from a peculiar and reversible acute cardiac ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Global death counts due to cardiovascular disease (CVD) increased from 12.4 million in 1990 to 19.8 million in 2022, reflecting global population growth and aging and the contributions from ...

Patients with heart failure (HF) who had an interatrial shunt inserted did not see any significant benefits overall, compared with those who underwent a placebo procedure, after a median 22-month ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...